Showing results (181-190 of 626) with videos related to

Sort By:
Pageof 63
Bulletin Du Cancer|September 7, 2023
Gynecological carcinosarcomas: Overview and future perspectivesLaetitia Collet, Andrea María González López, Clémence Romeo, et al.
Breast Cancer Research and Treatment|December 25, 2010
Chemotherapy for metastatic breast cancer. Comparison of clinical practice and cost of drugs in two cohorts of patients: 1994-1998 and 2003-2006Guillaume Galy, Sana Intidhar Labidi-Galy, David Perol, et al.
Health Promotion International|December 4, 2018
Openness to help-seeking for mental illness among Greek-CypriotsNektarios Alexi, Kathleen Moore, Marios Argyrides
Current Oncology Reports|February 27, 2019
Angiopoietin-1 and Angiopoietin-2 Inhibitors: Clinical DevelopmentJessica Gillen, Debra Richardson, Kathleen Moore
Gynecologic Oncology|May 18, 2011
Decreased hypersensitivity reactions with carboplatin-pegylated liposomal doxorubicin compared to carboplatin-paclitaxel combination: analysis from the GCIG CALYPSO relapsing ovarian cancer trialFlorence Joly, Isabelle Ray-Coquard, Michel Fabbro, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 1, 2004
Dendritic cell infiltration and prognosis of early stage breast cancerIsabelle Treilleux, Jean-Yves Blay, Nathalie Bendriss-Vermare, et al.
Frontiers in Oncology|November 28, 2022
Expanding the molecular spectrum of tenosynovial giant cell tumorsThibault Gauduchon, Helene Vanacker, Daniel Pissaloux, et al.
European Journal of Cancer (Oxford, England : 1990)|July 13, 2026
Clinical determinants, diagnostic complexity, and molecular heterogeneity in NF1-associated and sporadic malignant peripheral nerve sheath tumors: A 25-year referral-center cohortClio Coste, Mehdi Brahmi, Franck Tirode, et al.
NPJ Digital Medicine|June 20, 2026
Treatment-aware deep learning enables counterfactual prediction of individual benefit from PARP inhibitors in ovarian cancerJean-Sébastien Frenel, Pierre-Etienne Heudel, Emmanuelle Guinaudeau, et al.
BMC Cancer|February 18, 2011
Neoadjuvant imatinib in patients with locally advanced non metastatic GIST in the prospective BFR14 trialAurore Blesius, Philippe A Cassier, François Bertucci, et al.
Pageof 63